Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis ; volume:24 ; number:1 ; day:30 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (30.1.2024), 1-11, 12.2024
- Creator
-
Hildenbrand, Florian F.
Illi, Barbara
von Felten, Stefanie
Bachofner, Jacqueline
Gawinecka, Joanna
Eckardstein, Arnold von
Müllhaupt, Beat
Mertens, Joachim C.
Blümel, Sena
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-023-03116-4
- URN
-
urn:nbn:de:101:1-2024041012401869430625
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hildenbrand, Florian F.
- Illi, Barbara
- von Felten, Stefanie
- Bachofner, Jacqueline
- Gawinecka, Joanna
- Eckardstein, Arnold von
- Müllhaupt, Beat
- Mertens, Joachim C.
- Blümel, Sena
- SpringerLink (Online service)
Other Objects (12)
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients
Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients
Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
Copeptin und Suppressor-of-Tumorigenicity 2 (ST2) bei der Rechtsherzinsuffizienz
Altered behavior in mice overexpressing soluble ST2
Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia
Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction
Serum soluble ST2 is associated with ER-positive breast cancer
Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution
Soluble ST2 Predicts Poor Functional Outcome in Acute Ischemic Stroke Patients